Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus
| dc.creator | Gilda Aparecida Ferreira | |
| dc.creator | A. L. Teixeira | |
| dc.creator | Débora Cerqueira Calderaro | |
| dc.creator | Emília Inoue Sato | |
| dc.date.accessioned | 2023-07-19T20:27:38Z | |
| dc.date.accessioned | 2025-09-08T23:01:53Z | |
| dc.date.available | 2023-07-19T20:27:38Z | |
| dc.date.issued | 2016 | |
| dc.format.mimetype | ||
| dc.identifier.issn | 1593098X | |
| dc.identifier.uri | https://hdl.handle.net/1843/56768 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Clinical and Experimental Rheumatology | |
| dc.rights | Acesso Aberto | |
| dc.subject | Lúpus Eritematoso Sistêmico | |
| dc.subject | Aterosclerose | |
| dc.subject | Atorvastatina | |
| dc.subject.other | aterosclerose | |
| dc.subject.other | atorvastatin | |
| dc.subject.other | systemic lupus erythematosus | |
| dc.title | Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 48 | |
| local.citation.issue | 1 | |
| local.citation.spage | 42 | |
| local.citation.volume | 34 | |
| local.description.resumo | The aim of this study was to evaluate the efficacy of atorvastatin to reduce the plasma levels of TNF system molecules(TNF-α, sTNFR1 and sTNFR2) and to assess their association with risk factors for accelerate atherosclerosis and clinical disease activity scores in SLE patients.In a previous study, 64 female SLE patients received 20 mg/day of atorvastatin and 24 SLE patients (non-treated group)were followed for 8 weeks. Plasma levels of TNF-α, sTNFR 1 and sTNFR 2 were measured by ELISA, at baseline and atthe end of the study.The plasma levels of sTNFR1 and sTNFR 2 showed a positive correlation with SLEDAI score. We also found a positivecorrelation between TNF-α and sTNFR 1 levels and SLICC score. Patients with current nephritis and patients with anti-dsDNA antibodies presented higher sTNFR1 and sTNFR2 levels. Patients with abdominal obesity and arterial hypertension also had higher plasma levels of soluble receptors. At the end of 8 weeks, we observed a significant decrease in sTNFR1 plasma levels in patients receiving atorvastatin [median (percentile), 876.5 (717–1284 pg/ml) vs. 748 (629.6–917.3 pg/ml),p=0.03], without difference regarding TNF-α and sTNFR2 plasma levels. The SLEDAI and SLICC scores were independent determinants of the plasma levels of sRTNF1.Atorvastatin reduced soluble receptors of TNF-α. The plasma levels of TNF-α, sTNFR1 and sTNFR2 may play a role in SLE activity and atherosclerosis, and might be evaluated as targets for new therapies. | |
| local.publisher.country | Brasil | |
| local.publisher.department | MED - DEPARTAMENTO DE APARELHO LOCOMOTOR | |
| local.publisher.department | MED - DEPARTAMENTO DE CLÍNICA MÉDICA | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://www.clinexprheumatol.org/abstract.asp?a=9060 |